---
title: "HBM Holdings Forecasts Sharp Profit Surge on Recurring Biotech Collaboration Revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274755437.md"
description: "HBM Holdings Ltd. has issued a positive profit alert, forecasting an unaudited profit surge to between US$88 million and US$95 million for the year ending December 31, 2025, up from US$2.7 million the previous year. This growth is attributed to increased recurring revenue from global research collaborations and successful out-licensing. The company, listed on the Hong Kong Stock Exchange, focuses on biopharmaceutical collaborations and has a current market cap of HK$10.51 billion. The latest analyst rating for HBM Holdings is a Hold with a price target of HK$11.50."
datetime: "2026-02-04T00:10:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274755437.md)
  - [en](https://longbridge.com/en/news/274755437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274755437.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274755437.md) | [繁體中文](https://longbridge.com/zh-HK/news/274755437.md)


# HBM Holdings Forecasts Sharp Profit Surge on Recurring Biotech Collaboration Revenue

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

HBM Holdings Ltd. ( (HK:2142) ) has issued an update.

HBM Holdings Limited has issued a positive profit alert, indicating that its unaudited profit for the year ended 31 December 2025 is expected to surge to between US$88 million and US$95 million, compared with US$2.7 million a year earlier, with total adjusted profit forecast at US$91 million to US$98 million. Management attributes this sharp improvement to continued growth in recurring revenue from major global research collaborations, the successful conversion of out-licensing and product collaborations into stable revenue streams, and rapid expansion at subsidiary Nona Biosciences, which has contributed technology licence, platform service and milestone income, underscoring the Group’s strengthening commercialisation capabilities and deepening integration into the global biopharma value chain.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

**More about HBM Holdings Ltd.**

HBM Holdings Limited is a Cayman Islands-incorporated company listed on the Stock Exchange of Hong Kong, operating in the biopharmaceutical and life sciences sector. The Group focuses on platform-based research collaborations with global pharmaceutical companies and out-licensing of innovative products, with a growing base of recurring revenue from technology licences, platform services and milestone payments generated through partners such as AstraZeneca, Bristol Myers Squibb, Otsuka Pharmaceutical, Windward Bio and Pfizer.

**Average Trading Volume:** 4,580,667

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$10.51B

### Related Stocks

- [HBM HOLDINGS-B (02142.HK)](https://longbridge.com/en/quote/02142.HK.md)

## Related News & Research

- [19:01 ETHarbour BioMed Announces Positive Profit Alert for 2025 Annual Results](https://longbridge.com/en/news/274729678.md)
- [Shanghai Fudan-Zhangjiang Bio-Pharmaceutical subscribes to structured deposit product under Bank of China](https://longbridge.com/en/news/281521127.md)
- [Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data](https://longbridge.com/en/news/281082329.md)
- [Key facts: SK Hynix plans U.S. listing seeking ₩10–15T; HBM3/4 leader](https://longbridge.com/en/news/281622003.md)
- [Micron Technology Inc Stock (MU) Closed Up by 4.68% on Mar 31: A Full Analysis](https://longbridge.com/en/news/281237302.md)